Efficacy and safety of MPC-7869 (R-flurbiprofen), a selective ab42-lowering agent, in mild Alzheimer's disease (AD): Results of a 12-month Phase 2 trial and 1-year follow-on study

Efficacy and safety of MPC-7869 (R-flurbiprofen), a selective ab42-lowering agent, in mild Alzheimer's disease (AD): Results of a 12-month Phase 2 trial and 1-year follow-on study

書誌詳細
主要な著者:	Black, S, Wilcock, G, Haworth, J, Hendrix, S, Zavitz, K, Christensen, D, Binger, M, Bass, S, Laughlin, M, Swabb, E
フォーマット:	Conference item
出版事項:	2006

類似資料

Efficacy and safety of MPC-7869 (R-flurbiprofen), a Selective AB42-Lowering Agent, in Alzheimer's disease (AD): Results of a 12-month phase 2 trial and 1-year follow-on study.
著者:: Laughlin, M, 等
出版事項: (2006)

Flurizan, (MPC-7869, (R)-flurbiprofen) a selective A beta-42 lowering agent in patients with mild to moderate Alzheimer's disease: A randomised, placebo-controlled, double blind trial
著者:: Wilcock, G, 等
出版事項: (2005)

Efficacy and safety of tarenflurbil, a selective a beta 42-lowering agent, in Alzheimer's disease (AD): A phase 2 trial of up to 24 months of treatment
著者:: Black, S, 等
出版事項: (2008)

Efficacy and safety of tarenflurbil (flurizan), a selective Abeta42-lowering agent, in Alzheimer's disease (AD): A phase 2 trial of up to 24 months of treatment
著者:: Wilcock, G, 等
出版事項: (2007)

Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
著者:: Wilcock, G, 等
出版事項: (2008)

Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.
著者:: Green, R, 等
出版事項: (2009)

Disease-modifying treatments for Alzheimer's disease: a perspective based on experience with R-Flurbiprofen.
著者:: Wilcock, G
出版事項: (2006)

Population pharmacokinetic modeling of flurbiprofen, the active metabolite of flurbiprofen axetil, in Chinese patients with postoperative pain
著者:: Zhang J, 等
出版事項: (2018-11-01)

Population Pharmacokinetic Modeling of Flurbiprofen, the Active Metabolite of Flurbiprofen Axetil, in Chinese Patients with Postoperative Pain [Corrigendum]
著者:: Zhang J, 等
出版事項: (2020-03-01)

Formulation and Evaluation of Flurbiprofen Oral Film
著者:: Shaimaa N. Abd-Alhammid, 等
出版事項: (2017-03-01)

Formulation and Evaluation of Flurbiprofen Oral Film
著者:: Shaimaa N. Abd-Alhammid, 等
出版事項: (2017-02-01)

Formulation and Evaluation of Flurbiprofen Oral Film
著者:: Shaimaa N. Abd-Alhammid, 等
出版事項: (2017-03-01)

Use of Flurbiprofen Ester in 4-Dimensional Hysterosalpingography: Does Flurbiprofen Ester Relieve Pain During an Infertility Evaluation?
著者:: Long Tan, 等
出版事項: (2024-07-01)

Population Pharmacokinetic Modeling Of Flurbiprofen, The Active Metabolite Of Flurbiprofen Axetil, In Chinese Patients With Postoperative Pain [Expression Of Concern]
著者:: Zhang J, 等
出版事項: (2019-09-01)

The Comparison of Plasma and Cerebrospinal Fluid R(−)- and S(+)-Flurbiprofen Concentration After Intravenous Injection of Flurbiprofen Axetil in Human Subjects
著者:: Han Yao, 等
出版事項: (2021-04-01)

Ethylenediamine Salt Enhances the Solubility and Dissolution of Flurbiprofen
著者:: Dr. Lei Gao, 等
出版事項: (2024-06-01)

Physicochemical, in vitro and in vivo evaluation of flurbiprofen microemulsion
著者:: MUHAMMAD NAEEM, 等
出版事項: (2015-09-01)

Formulation and evaluation of co-prodrug of flurbiprofen and methocarbamol
著者:: Neela Bhatia, 等
出版事項: (2016-06-01)

Abnormal visual search in mild cognitive impairment and Alzheimer's disease.
著者:: Tales, A, 等
出版事項: (2005)

A Luminous Dust-obscured Tidal Disruption Event Candidate in a Star-forming Galaxy at 42 Mpc
著者:: Christos Panagiotou, 等
出版事項: (2023-01-01)

Abnormal spatial and non-spatial cueing effects in mild cognitive impairment and Alzheimer's disease.
著者:: Tales, A, 等
出版事項: (2005)

R‐flurbiprofen attenuates experimental autoimmune encephalomyelitis in mice
著者:: Katja Schmitz, 等
出版事項: (2014-09-01)

Flurbiprofen ameliorates glucose deprivation-induced leptin resistance
著者:: Toru Hosoi, 等
出版事項: (2016-09-01)

Effect of flurbiprofen axetil on postoperative delirium for elderly patients
著者:: Xifan Wang, 等
出版事項: (2019-06-01)

FANNG-MPC: Framework for Artificial Neural Networks and Generic MPC
著者:: Najwa Aaraj, 等
出版事項: (2024-12-01)

Control of Bioethanol Fermentation Process: NARX-Based MPC (NARX-MPC) versus Linear-Based MPC (LMPC)
著者:: N. Mohd, 等
出版事項: (2015-09-01)

Single dose oral flurbiprofen for acute postoperative pain in adults.
著者:: Sultan, A, 等
出版事項: (2009)

Measurement and modeling of solubilities of flurbiprofen in modified supercritical carbon dioxide.
著者:: Chin, Gui Jin.
出版事項: (2009)

15-LOX Inhibitors: Biochemical Evaluation of Flurbiprofen and its Derivatives
著者:: Saghir Abbas, 等
出版事項: (2020-07-01)

Case Report: Flurbiprofen-induced Type I Kounis syndrome
著者:: Chao Tang, 等
出版事項: (2023-11-01)

Preparation and evaluation of oral soft chewable jelly containing flurbiprofen
著者:: Lubna Abdalkarim Sabri, 等
出版事項: (2022-01-01)

Enantioselective esterification of (R,S)-flurbiprofen catalyzed by lipase in ionic liquid
著者:: Ruihong Zhao, 等
出版事項: (2017-01-01)

Metal organic frameworks as a drug delivery system for flurbiprofen
著者:: AL Haydar M, 等
出版事項: (2017-09-01)

Determination of the Permeation and Penetration of Flurbiprofen into Cadaveric Human Pharynx Tissue
著者:: Turner R, 等
出版事項: (2020-03-01)

Investigation of the parameters affecting the release of flurbiprofen from chitosan microspheres
著者:: Müşerref Günseli Yüksel Tilkan, 等
出版事項: (2018-04-01)

Visual search in mild cognitive impairment: a longitudinal study.
著者:: Tales, A, 等
出版事項: (2011)

Visual mismatch negativity highlights abnormal pre-attentive visual processing in mild cognitive impairment and Alzheimer's disease.
著者:: Tales, A, 等
出版事項: (2008)

Ab initio calculations for well deformed nuclei: 40Mg and 42Si
著者:: Q. Yuan, 等
出版事項: (2024-01-01)

Determination of the Lipophilicity of Ibuprofen, Naproxen, Ketoprofen, and Flurbiprofen with Thin-Layer Chromatography
著者:: Andrzej Czyrski
出版事項: (2019-01-01)

Mechanistic Investigation into Crystallization of Hydrated Co-Amorphous Systems of Flurbiprofen and Lidocaine
著者:: Xiaoyue Xu, 等
出版事項: (2025-01-01)